Neuro-Oncology Reviews
Volume
28 Number 24
31 August 2026
Home > Publications > Neuro-Oncology Reviews > Volume 28, Year 2026 > Number 24, 31 August
Alomari O, Alomari T, Güney B, Eyvazova H, Benamara TS,
Alomari S, Bingöl M, Odabas H.
Systemic
and local dysregulation of the complement system in glioma: a
comprehensive systematic review.
Clin
Transl Oncol. 2026 Aug 21. doi:
10.1007/s12094-026-04552-w. PMID:
42627589˰ ˍ
Chen L, Zou Z.
CAR-T Cell Therapy for
Glioblastoma: Obstacles and Advances.
Crit
Rev Oncol Hematol. 2026 Aug 21;227:105556. doi:
10.1016/j.critrevonc.2026.105556. PMID:
42628610. ˍ
Qiu Q, Zhang T, Song P, Deng H, Liu Y, Bu J, Zhang M.
Decoding
the spatiotemporal dynamics of T cell immune landscapes in
glioblastoma: remodeling precision combination therapies.
Biochim
Biophys Acta Rev Cancer. 2026 Aug 21;1881(5):189691.
doi:
10.1016/j.bbcan.2026.189691. PMID:
42628660. ˍ
Liu Y, Guo C, Wang X, Huang K, Huang S, Cao J, Deng M, Guan T,
Zhang Y, Tian S, Zheng Z.
The
Brain-tumor axis: Tumor pathogenesis and therapeutic strategies
from a cancer neuroscience perspective.
Cancer
Treat Res Commun. 2026 Aug 22;49:101384. doi:
10.1016/j.ctarc.2026.101384. PMID:
42632358. ˍ
Nageeb G, Ha JH, Liu J, Sjoholm MA, Lim M.
Immunotherapy
for Glioma: A compartmental framework for resistance and rational
combination design.
Neurotherapeutics.
2026 Aug 22;23(6):e01035. doi:
10.1016/j.neurot.2026.e01035. PMID:
42632152. ˍ
Nassor M, Chaudhry S, Zahin F, Roy S, Odei KPK, Nkrumah-Boateng
PA, Wireko AA.
Ferroptosis as an
immunometabolic checkpoint in brain tumours: spatial
vulnerabilities and therapeutic opportunities.
Mol
Brain. 2026 Aug 24;19(1):63. doi:
10.1186/s13041-026-01344-9. PMID:
42638114. ˍ
Raut S, Bhatt LK.
Targeting
glioblastoma epigenetics: mechanisms, microenvironmental
interplay, and therapeutic potential.
Neuroscience.
2026 Aug 25;615:102-119. doi:
10.1016/j.neuroscience.2026.08.039. PMID:
42641911˰ ˍ
Jabri A, Mhannayeh A, Taftafa B, Alsharif M, Sibai D, Alsharif R,
Abbad T, Elsalti A, Ahmed Z, Salma J, Khan MI, Yaqinuddin
A.
Recent advances in immunotherapy for
gliomas: overcoming barriers and advancing precision strategies.
Front
Immunol. 2026 Jan 8;16:1690464. doi:
10.3389/fimmu.2025.1690464. PMID:
41583467. ˍ
Schonfeld E, Sjoholm A, Ha J, Liu J, Nageeb G, Annagiri S, Kim L,
Choi J, Lim M.
Next-generation
immunotherapy biologics for glioblastoma.
Front
Immunol. 2026 Mar 18;17:1775093. doi:
10.3389/fimmu.2026.1775093. PMID:
41929511. ˍ
Hill CM, Nwagwu CD, Odukoya AO, Hsueh B, Wang AZ, Dunn GP.
Tumor
infiltrating lymphocytes in glioblastoma: immunobiology and
translational implications.
NPJ
Precis Oncol. 2026 Jul 13;10(1):274. doi:
10.1038/s41698-026-01330-3. PMID:
42437767. ˍ
Figueira K, Pigott LE.
Outcomes of
target therapies for pediatric BRAF V600-mutant low-grade gliomas:
A systematic review and meta-analysis.
Neurooncol
Adv. 2026 Jul 27;8(1):vdag192. doi:
10.1093/noajnl/vdag192. PMID:
42633479. ˍ
Walton CM, Strickland BA.
Complement-Targeted
Therapies in Glioblastoma: A Systematic Review.
Biomedicines.
2026 Jul 29;14(8):1702. doi:
10.3390/biomedicines14081702. PMID:
42652085. ˍ
Sarrazin E, Valable S, Pérès EA, Colloc'h N, Emery
E, Lesueur P, Leclerc A, Bernaudin M, Aury-Landas J.
Glioblastoma
and resistance to radiotherapy: role of cancer stem cells
subpopulations, hypoxia and therapeutic strategies.
Cancer
Treat Rev. 2026 Aug 1;149:103198. doi:
10.1016/j.ctrv.2026.103198. PMID:
42659714. ˍ
Chao CC, Shen HE, Zhang BB, Chao TC, Wang CW, Wu CC.
Challenges
and Opportunities of γδ T Cell-Based Immunotherapy for
Glioblastoma.
Biomedicines.
2026 Aug 6;14(8):1770. doi:
10.3390/biomedicines14081770. PMID:
42652153. ˍ
Elemam NM, Sweillam JH, El-Sherif Y, Youssef YA, Ismail HM, Assal
RA, Youness RA.
Long non-coding RNAs
in glioblastoma: from molecular drivers to therapeutic targets.
Front
Immunol. 2026 Aug 7;17:1887815. doi:
10.3389/fimmu.2026.1887815. PMID:
42630738. ˍ
Russo F, Ricci M, Dadgar H, Travascio L, De Feo MS, Brunotti G,
Usmani S, Arabi H, Anwar FM, Khalaf AN, Filippi L, Cimini
A.
PSMA-Targeted Theranostics in
Glioblastoma Multiforme: Current Evidence and Future Perspectives.
Int
J Mol Sci. 2026 Aug 8;27(16):7112. doi:
10.3390/ijms27167112. PMID:
42653114. ˍ
Aydın HA, Keskin E, Kalaycı M.
Reprogramming
the immunosuppressive microenvironment in glioblastoma: the
microglia-MDSC-Treg axis and translational therapeutic strategies.
Front
Oncol. 2026 Aug 10;16:1782775. doi:
10.3389/fonc.2026.1782775. PMID:
42639384. ˍ
Prajapati S, Yadav S.
Engineered
Exosomes as Next-generation Nanotherapeutics for Glioma: Crossing
the Blood-brain Barrier Toward Precision Medicine.
Curr
Neurovasc Res. 2026 Aug 10. doi:
10.2174/0115672026464128260804075922. PMID:
42634375. ˍ
Tianqing Z, Yuan G, Qianyi Y, Yanchu L.
Review
of glioblastoma and systemic comorbidities.
Front
Oncol. 2026 Aug 10;16:1882982. doi:
10.3389/fonc.2026.1882982. PMID:
42639360. ˍ
Lichtor T, O-Sullivan I, Tang B.
Editorial:
Immunotherapeutic advances in brain tumours.
Front
Immunol. 2026 Aug 12;17:1949875. doi:
10.3389/fimmu.2026.1949875. PMID:
42657017. ˍ
Eddy EM, Patton T, Barrow AD, Corbett AJ.
Unconventional
guardians of the brain: MAIT cells as emerging players in
glioblastoma immunity.
Front
Immunol. 2026 Aug 13;17:1896626. doi:
10.3389/fimmu.2026.1896626. PMID:
42662577. ˍ
Cantor E, Qutob H, Ayers J, Donnville B, Nieves C, Cruz-Flores V,
Stapleton S, Patel NJ.
Report from the
National Pediatric Cancer Foundation - infantile glioma and other
non-embryonal central nervous system tumors: evolving molecular
advances and current treatment landscape.
Front
Oncol. 2026 Aug 14;16:1874371. doi:
10.3389/fonc.2026.1874371. PMID:
42666540. ˍ
Engelhardt B, Platten M.
Brain
barriers at the crossroads of glioma immune surveillance and
immunotherapy response.
Nat
Rev Cancer. 2026 Aug 20. doi:
10.1038/s41568-026-00960-w. PMID:
42624896˰ ˍ